(Reuters) – Gilead Sciences Inc (NASDAQ:) reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.
Remdesivir brought in $873 million in the third quarter ended Sept. 30, below analysts’ estimates of $960 million, according to Refinitiv IBES data.
Remdesivir, given intravenously, won formal U.S. approval last week, but the drug has been available under an FDA emergency use authorization since May.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.